Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | APP | P05067 | 1/20 | 1.00 |
| ▸ | GBA1 | P04062 | 4/20 | 0.50 |
| ▸ | MGAM | O43451 | 6/20 | 0.33 |
| ▸ | FUCA1 | P04066 | 5/20 | 0.33 |
| ▸ | GLA | P06280 | 2/20 | 0.33 |
| ▸ | GANC | Q8TET4 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.31 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Scyllitol SCHEMBL6378921 | 1.00 | LMNA (1.00) | LMNAAPPGBA1MGAMFUCA1 | |
| Scyllitol SCHEMBL4447990 | 1.00 | LMNA (1.00) | LMNAAPPGBA1MGAMFUCA1 | |
| Scyllitol SCHEMBL4438767 | 1.00 | LMNA (1.00) | LMNAAPPGBA1MGAMFUCA1 | |
| Scyllitol SCHEMBL12377889 | 1.00 | LMNA (1.00) | LMNAAPPGBA1MGAMFUCA1 | |
| Scyllitol SCHEMBL21388397 | 1.00 | LMNA (1.00) | LMNAAPPGBA1MGAMFUCA1 | |
| Scyllitol SCHEMBL5969 | 1.00 | LMNA (1.00) | LMNAAPPGBA1MGAMFUCA1 | |
| Scyllitol SCHEMBL959405 | 1.00 | LMNA (1.00) | LMNAAPPGBA1MGAMFUCA1 | |
| Scyllitol SCHEMBL188237 | 1.00 | LMNA (1.00) | LMNAAPPGBA1MGAMFUCA1 | |
| Scyllitol SCHEMBL188106 | 1.00 | LMNA (1.00) | LMNAAPPGBA1MGAMFUCA1 | |
| SCHEMBL1963355 | 1.00 | LMNA (1.00) | LMNAAPPGBA1MGAMFUCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11707470-B2 | Inositol derivatives for use in pathological crystallization | ETH ZURICH (CH) | 2023-07-25 | — | — | US | disclosed |
| US-20210290643-A1 | INOSITOL DERIVATIVES FOR USE IN PATHOLOGICAL CRYSTALLIZATION | ETH ZURICH (CH) | 2021-09-23 | — | — | US | disclosed |
| US-11028112-B2 | Inositol derivatives for use in pathological crystallization | ETH ZURICH (CH) | 2021-06-08 | — | — | US | disclosed |
| EP-3231804-B1 | COMPOUNDS AND COMPOSITIONS FOR THE DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS | MASSACHUSETTS GEN HOSPITAL (US) | 2021-03-03 | — | — | EP | disclosed |
| US-10857247-B2 | Compounds and compositions for the detection and treatment of Alzheimer's disease and related disorders | THE GENERAL HOSPITAL CORPORATION (US) | 2020-12-08 | — | — | US | disclosed |
| US-20200368173-A1 | NUCLEIC ACID-CONTAINING LIPID NANOPARTICLE | KYOWA KIRIN CO., LTD. (JP) | 2020-11-26 | — | — | US | disclosed |
| US-20200247837-A1 | INOSITOL DERIVATIVES FOR USE IN PATHOLOGICAL CRYSTALLIZATION | ETH ZURICH (CH) | 2020-08-06 | — | — | US | disclosed |
| US-10624909-B2 | Inositol derivatives for use in pathological crystallization | ETH ZURICH (CH) | 2020-04-21 | — | — | US | disclosed |
| WO-2019204808-A1 | ACETYLATED PRODRUGS FOR DELIVERY ACROSS THE BLOOD-BRAIN BARRIER | THE GENERAL HOSPITAL CORPORATION (US) | 2019-10-24 | — | — | WO | disclosed |
| US-20190175627-A1 | INOSITOL DERIVATIVES FOR USE IN PATHOLOGICAL CRYSTALLIZATION | ETH ZURICH (CH) | 2019-06-13 | — | — | US | disclosed |
| US-9738675-B2 | Water-soluble photochromic compound | RIKKYO EDUCATIONAL CORPORATION (JP) | 2017-08-22 | — | — | US | disclosed |
| EP-2902402-A1 | WATER-SOLUBLE PHOTOCHROMIC MOLECULE | Rikkyo Educational Corporation (JP) | 2015-08-05 | — | — | EP | disclosed |
| US-20110207188-A1 | Scyllo-Inositol-Producing Cell and Scyllo-Inositol Production Method Using Said Cells | NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY (JP) | 2011-08-25 | — | — | US | disclosed |
| WO-2011100670-A1 | PROCESS FOR THE PREPARATION OF SCYLLO-INOSITOL | ABBOTT LABORATORIES (US) | 2011-08-18 | — | — | WO | disclosed |
| US-20110201060-A1 | PROCESS FOR THE PREPARATION OF SCYLLO-INOSITOL | ABBOTT LABORATORIES (US) | 2011-08-18 | — | — | US | disclosed |
| EP-2298870-A1 | Method for producing scyllo-inositol | Hokko Chemical Industry Co., Ltd. (JP) | 2011-03-23 | — | — | EP | disclosed |
| US-20100261238-A1 | METHOD FOR PRODUCING SCYLLO-INOSITOL | HOKKO CHEMICAL INDUSTRY CO., LTD. (JP) | 2010-10-14 | — | — | US | disclosed |
| US-7745671-B2 | Industrial scale synthesis; used in treatment of Alzheimer's disease or as raw material in synthesis; forming a boric acid and scylloinositol complex | HOKKO CHEMICAL INDUSTRY CO., LTD. (JP) | 2010-06-29 | — | — | US | disclosed |
| US-20090326013-A1 | ISOMERS OF INOSITOL NIACINATE AND USES THEREOF | CONCOURSE HEALTH SCIENCES LLC | 2009-12-31 | — | — | US | disclosed |
| EP-2058390-A1 | Method for producing scyllo-inositol | HOKKO CHEMICAL INDUSTRY CO., LTD. (JP) | 2009-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326013-A1 | ISOMERS OF INOSITOL NIACINATE AND USES THEREOF | NAPRT, NR1H2, NR1H4 | LMNA 2654/4885APP 3313/4885GBA1 1162/4885 |
| US-10624909-B2 | Inositol derivatives for use in pathological crystallization | PPIP5K2, IPMK, ITPR2 | LMNA 995/4885APP 1793/4885GBA1 1487/4885 |
| US-20190175627-A1 | INOSITOL DERIVATIVES FOR USE IN PATHOLOGICAL CRYSTALLIZATION | PPIP5K2, IPMK, ITPR2 | LMNA 995/4885APP 1793/4885GBA1 1487/4885 |
| US-10857247-B2 | Compounds and compositions for the detection and treatment of Alzheimer's disease and related disorders | APP, PSEN1, PSEN2 | LMNA 1527/4885APP 1/4885GBA1 15/4885 |
| US-11028112-B2 | Inositol derivatives for use in pathological crystallization | PPIP5K2, IPMK, ITPR2 | LMNA 995/4885APP 1793/4885GBA1 1487/4885 |
| US-20200247837-A1 | INOSITOL DERIVATIVES FOR USE IN PATHOLOGICAL CRYSTALLIZATION | PPIP5K2, IPMK, ITPR2 | LMNA 995/4885APP 1793/4885GBA1 1487/4885 |
| US-11707470-B2 | Inositol derivatives for use in pathological crystallization | ITPR3, PPIP5K2, ITPR2 | LMNA 1906/4885APP 992/4885GBA1 292/4885 |
| US-20210290643-A1 | INOSITOL DERIVATIVES FOR USE IN PATHOLOGICAL CRYSTALLIZATION | ITPR3, PPIP5K2, ITPR2 | LMNA 1906/4885APP 992/4885GBA1 292/4885 |
| US-20200368173-A1 | NUCLEIC ACID-CONTAINING LIPID NANOPARTICLE | LIPA, LIPC, PNLIP | LMNA 570/4885APP 4316/4885GBA1 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.